` APTO (Aptose Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

APTO
vs
S&P 500

Over the past 12 months, APTO has underperformed S&P 500, delivering a return of -91% compared to the S&P 500's 10% growth.

Stocks Performance
APTO vs S&P 500

Loading
APTO
S&P 500
Add Stock

Performance Gap
APTO vs S&P 500

Loading
APTO
S&P 500
Difference
www.alphaspread.com

Performance By Year
APTO vs S&P 500

Loading
APTO
S&P 500
Add Stock

Competitors Performance
Aptose Biosciences Inc vs Peers

S&P 500
APTO
ABBV
AMGN
GILD
VRTX
Add Stock

Aptose Biosciences Inc
Glance View

Market Cap
5.1m USD
Industry
Biotechnology

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in North York, Ontario and currently employs 41 full-time employees. The firm has two clinical-stage investigational products for hematologic malignancies: luxeptinib and APTO-253. The luxeptinib is a mutation agnostic Bruton’s tyrosine kinase (BTK) kinase inhibitor, which is in a Phase I a/b trial in patients with refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies and is in a separate Phase I a/b trial in patients with refractory acute myeloid leukemia (AML). Its APTO-253 is the clinical stage agent that directly targets the Master Regulator of Cell Cycle Entry and Proliferative Metabolism (MYC) oncogene and suppresses its expression, which is in a Phase I a/b clinical trial for the treatment of patients with relapsed.

APTO Intrinsic Value
Not Available
A
Back to Top